|Study Description:||The purpose of this study is to evaluate the effectiveness of ibrutinib in |
patients with relapsed or refractory B-ALL as measured by objective response
rate. The safety of ibrutinib in patients with relapsed or refractory B-ALL
will be studied. The response duration will be assessed . The Bruton’s
Tyrosine Kinase (BTK) target inhibition, biomarkers, and gene expression
profiles in B-ALL patient will also be studied.